Discover and read the best of Twitter Threads about #sarilumab
Most recents (7)
Anti IL-6 en pacientes críticamente enfermos con Covid-19 - Informe preliminar.
Investigadores de REMAP-CAP.
medrxiv.org/content/10.110…
Investigadores de REMAP-CAP.
medrxiv.org/content/10.110…
El ensayo muestra que los pacientes que reciben tocilizumab y un segundo fármaco : sarilumab, pueden reducir el riesgo relativo de muerte en un 24% cuando se administran a los pacientes dentro de las 24 horas posteriores al ingreso en cuidados intensivos.
Los pacientes tienen un impacto significativo en la supervivencia.
nihr.ac.uk/news/arthritis…
nihr.ac.uk/news/arthritis…
@remap_cap is proud to announce the findings of IL-6 blockade in critically ill patients with #COVID19.
medrxiv.org/cgi/content/sh… (1/10)
medrxiv.org/cgi/content/sh… (1/10)
353 patients randomized to #tocilizumab, 48 to #sarilumab, and 402 to control.
Adjusted odds ratio for improvement on organ-support free days at day 21 was 1.64 (CrI 1.25 - 2.18) and 1.89 (1.24 - 3.48), respectively. (2/10)
Adjusted odds ratio for improvement on organ-support free days at day 21 was 1.64 (CrI 1.25 - 2.18) and 1.89 (1.24 - 3.48), respectively. (2/10)
Mortality was 28% with tocilizumab, 22.2% for sarilumab (combined 27.3%), and 35.8% for control, with benefit of IL-6 blockade on all secondary outcomes collected. (3/10)
#NewsApp Actualizamos toda la evidencia que hasta ahora se conoce sobre los tratamientos contra el COVID-19 con el gran aporte de @EpistemonikosEs. Hoy también encontrarán novedades: la #Hidrocortisona [Hilo]
saludconlupa.com/comprueba/cien…
saludconlupa.com/comprueba/cien…
Ahora sabemos la #hidrocortisona, un corticoide al igual que dexametasona, funciona para el tratamiento de casos graves de COVID-19 (aquellos que requieren atención en unidades de cuidados intensivos). La OMS recopiló los resultados de todos los ensayos que lo confirman.
Las nuevas revisiones permiten conocer también que #tocilizumab, #sarilumab y #azitromicina bajaron su clasificación de evidencia y son ahora poco prometedores como terapia COVID-19.
👨🔬👩🔬🧪saludconlupa.com/terapias-covid…
👨🔬👩🔬🧪saludconlupa.com/terapias-covid…
How we’ll we manage the first ten #COVID19 patients of 2021 (if any) hospitalized for #ARDS (compared to the first 10 patients we managed in February 2020). A multidisciplinary brain storming after managing approx 1000 such patients within the end of Apr 2020. A thread 1/ #FOAMed
2/
Not all our clinical impressions have already published evidence (but the majority was published), but our hospital #COVID19 mortality went close to zero in late April 2020 and we hope medical management accounts for at least part of these results.
Not all our clinical impressions have already published evidence (but the majority was published), but our hospital #COVID19 mortality went close to zero in late April 2020 and we hope medical management accounts for at least part of these results.
3/
More, early ECMO. We put a dozen ECMO. We feel we should have put more of them and we should have done it earlier (eg after a couple of days of invasive mechanical ventilation with no improvement). @annamarascandro
@mgcalabroMD @md_monaco @MarinaPieri4
hsr.it/news/2020/magg…
More, early ECMO. We put a dozen ECMO. We feel we should have put more of them and we should have done it earlier (eg after a couple of days of invasive mechanical ventilation with no improvement). @annamarascandro
@mgcalabroMD @md_monaco @MarinaPieri4
hsr.it/news/2020/magg…
1/
I want to thank all my colleagues for the wonderful #COVID19 research they published during these months: >200 PubMed-indexed articles from @SanRaffaeleMI @SRAnesthesiaICU @MyUniSR @azangrillo
I’ll summarize few of them in this thread.
I want to thank all my colleagues for the wonderful #COVID19 research they published during these months: >200 PubMed-indexed articles from @SanRaffaeleMI @SRAnesthesiaICU @MyUniSR @azangrillo
I’ll summarize few of them in this thread.
2/
In February, before the start of #COVID19 in Europe, we suggested the use of helmet to deliver #CPAP #NIV in emergency departments. This can be a key issue to prevent future spread of respiratory pandemics in emergency departments.
thelancet.com/journals/lance…
In February, before the start of #COVID19 in Europe, we suggested the use of helmet to deliver #CPAP #NIV in emergency departments. This can be a key issue to prevent future spread of respiratory pandemics in emergency departments.
thelancet.com/journals/lance…
3/
As soon as #COVID19 spread in Lombardy we helped other centers to manage their worst patients: 39 patients from other centers were admitted in our ICUs. The H was reshaped to cope with the new situation. The manusc cited 38 times in the first 4 months.
As soon as #COVID19 spread in Lombardy we helped other centers to manage their worst patients: 39 patients from other centers were admitted in our ICUs. The H was reshaped to cope with the new situation. The manusc cited 38 times in the first 4 months.
Starting a series on clinical Pearls I am gathering in #COVID19 patients based on experiences of many experts
Will add as we go along
Feel free to add your own observations/experiences
#covidclinicalpearls /1
Will add as we go along
Feel free to add your own observations/experiences
#covidclinicalpearls /1
Anosmia is likely the most specific #COVID19 related symptom
30% of patients have anosmia as their 1st symptom
#covidclinicalpearls /2
30% of patients have anosmia as their 1st symptom
#covidclinicalpearls /2
Around 90% of patients have fever.
50% maybe afebrile at the time of presentation
Fever tends to be very resistant to routine measures in hospitalized patients
There is no consensus that NSAIDs are to be avoided in #COVID2019 patients
#covidclinicalpearls /3
50% maybe afebrile at the time of presentation
Fever tends to be very resistant to routine measures in hospitalized patients
There is no consensus that NSAIDs are to be avoided in #COVID2019 patients
#covidclinicalpearls /3
There is no proven effective antiviral drug for the treatment of #SARSCoV2
Several compounds are suggested for Rx of #COVID19. Based on the available in vitro and clinical data, which one is your preferred Rx, if available? #MayoIDQ references follow...
Several compounds are suggested for Rx of #COVID19. Based on the available in vitro and clinical data, which one is your preferred Rx, if available? #MayoIDQ references follow...
1/
#Chloroquine
Anti-malaria
Several potential mechanisms: change in cell membrane pH, impairs viral fusion, interferes with glycosylation of viral proteins
#chloroquine and #redemsivir are active against SARS-COV2 in experimental models
doi.org/10.1038/s41422…
#Chloroquine
Anti-malaria
Several potential mechanisms: change in cell membrane pH, impairs viral fusion, interferes with glycosylation of viral proteins
#chloroquine and #redemsivir are active against SARS-COV2 in experimental models
doi.org/10.1038/s41422…
2/
#Hydroxychloroquine
- Analogue of chloroquine
- Anti inflammatory effect
Hydroxychloroquine was more potent than chloroquine against #SARS-CoV2 in vitro.
doi.org/10.1093/cid/ci…
#Hydroxychloroquine
- Analogue of chloroquine
- Anti inflammatory effect
Hydroxychloroquine was more potent than chloroquine against #SARS-CoV2 in vitro.
doi.org/10.1093/cid/ci…
